Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

62 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Monoclonal antibodies against the spike protein alter the endogenous humoral response to SARS-CoV-2 vaccination and infection.
Petro CD, Hooper AT, Peace A, Mohammadi K, Eagan W, Elbashir SM, DiPiazza A, Makrinos D, Pascal K, Bandawane P, Durand M, Basu R, Coppi A, Wang B, Golubov J, Asrat S, Ganguly S, Koehler-Stec EM, Wipperman MF, Ehrlich G, Gonzalez Ortiz AM, Isa F, Lewis MG, Andersen H, Musser BJ, Torres M, Lee WY, Edwards D, Skokos D, Orengo J, Sleeman M, Norton T, O'Brien M, Forleo-Neto E, Herman GA, Hamilton JD, Murphy AJ, Kyratsous CA, Baum A. Petro CD, et al. Among authors: hooper at. Sci Transl Med. 2024 Nov 6;16(772):eadn0396. doi: 10.1126/scitranslmed.adn0396. Epub 2024 Nov 6. Sci Transl Med. 2024. PMID: 39504352
REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19.
Weinreich DM, Sivapalasingam S, Norton T, Ali S, Gao H, Bhore R, Musser BJ, Soo Y, Rofail D, Im J, Perry C, Pan C, Hosain R, Mahmood A, Davis JD, Turner KC, Hooper AT, Hamilton JD, Baum A, Kyratsous CA, Kim Y, Cook A, Kampman W, Kohli A, Sachdeva Y, Graber X, Kowal B, DiCioccio T, Stahl N, Lipsich L, Braunstein N, Herman G, Yancopoulos GD; Trial Investigators. Weinreich DM, et al. Among authors: hooper at. N Engl J Med. 2021 Jan 21;384(3):238-251. doi: 10.1056/NEJMoa2035002. Epub 2020 Dec 17. N Engl J Med. 2021. PMID: 33332778 Free PMC article. Clinical Trial.
The monoclonal antibody combination REGEN-COV protects against SARS-CoV-2 mutational escape in preclinical and human studies.
Copin R, Baum A, Wloga E, Pascal KE, Giordano S, Fulton BO, Zhou A, Negron N, Lanza K, Chan N, Coppola A, Chiu J, Ni M, Wei Y, Atwal GS, Hernandez AR, Saotome K, Zhou Y, Franklin MC, Hooper AT, McCarthy S, Hamon S, Hamilton JD, Staples HM, Alfson K, Carrion R Jr, Ali S, Norton T, Somersan-Karakaya S, Sivapalasingam S, Herman GA, Weinreich DM, Lipsich L, Stahl N, Murphy AJ, Yancopoulos GD, Kyratsous CA. Copin R, et al. Among authors: hooper at. Cell. 2021 Jul 22;184(15):3949-3961.e11. doi: 10.1016/j.cell.2021.06.002. Epub 2021 Jun 5. Cell. 2021. PMID: 34161776 Free PMC article. Clinical Trial.
Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19.
O'Brien MP, Forleo-Neto E, Musser BJ, Isa F, Chan KC, Sarkar N, Bar KJ, Barnabas RV, Barouch DH, Cohen MS, Hurt CB, Burwen DR, Marovich MA, Hou P, Heirman I, Davis JD, Turner KC, Ramesh D, Mahmood A, Hooper AT, Hamilton JD, Kim Y, Purcell LA, Baum A, Kyratsous CA, Krainson J, Perez-Perez R, Mohseni R, Kowal B, DiCioccio AT, Stahl N, Lipsich L, Braunstein N, Herman G, Yancopoulos GD, Weinreich DM; Covid-19 Phase 3 Prevention Trial Team. O'Brien MP, et al. Among authors: hooper at. N Engl J Med. 2021 Sep 23;385(13):1184-1195. doi: 10.1056/NEJMoa2109682. Epub 2021 Aug 4. N Engl J Med. 2021. PMID: 34347950 Free PMC article. Clinical Trial.
REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19.
Weinreich DM, Sivapalasingam S, Norton T, Ali S, Gao H, Bhore R, Xiao J, Hooper AT, Hamilton JD, Musser BJ, Rofail D, Hussein M, Im J, Atmodjo DY, Perry C, Pan C, Mahmood A, Hosain R, Davis JD, Turner KC, Baum A, Kyratsous CA, Kim Y, Cook A, Kampman W, Roque-Guerrero L, Acloque G, Aazami H, Cannon K, Simón-Campos JA, Bocchini JA, Kowal B, DiCioccio AT, Soo Y, Geba GP, Stahl N, Lipsich L, Braunstein N, Herman G, Yancopoulos GD; Trial Investigators. Weinreich DM, et al. Among authors: hooper at. N Engl J Med. 2021 Dec 2;385(23):e81. doi: 10.1056/NEJMoa2108163. Epub 2021 Sep 29. N Engl J Med. 2021. PMID: 34587383 Free PMC article. Clinical Trial.
Anti-SARS-CoV-2 IgA Identifies Asymptomatic Infection in First Responders.
Montague BT, Wipperman MF, Hooper AT, Hamon SC, Crow R, Elemo F, Hersh L, Langdon S, Hamilton JD, O'Brien MP, Simões EAF. Montague BT, et al. Among authors: hooper at. J Infect Dis. 2022 Feb 15;225(4):578-586. doi: 10.1093/infdis/jiab524. J Infect Dis. 2022. PMID: 34636907 Free PMC article.
Effect of Subcutaneous Casirivimab and Imdevimab Antibody Combination vs Placebo on Development of Symptomatic COVID-19 in Early Asymptomatic SARS-CoV-2 Infection: A Randomized Clinical Trial.
O'Brien MP, Forleo-Neto E, Sarkar N, Isa F, Hou P, Chan KC, Musser BJ, Bar KJ, Barnabas RV, Barouch DH, Cohen MS, Hurt CB, Burwen DR, Marovich MA, Brown ER, Heirman I, Davis JD, Turner KC, Ramesh D, Mahmood A, Hooper AT, Hamilton JD, Kim Y, Purcell LA, Baum A, Kyratsous CA, Krainson J, Perez-Perez R, Mohseni R, Kowal B, DiCioccio AT, Geba GP, Stahl N, Lipsich L, Braunstein N, Herman G, Yancopoulos GD, Weinreich DM; COVID-19 Phase 3 Prevention Trial Team. O'Brien MP, et al. Among authors: hooper at. JAMA. 2022 Feb 1;327(5):432-441. doi: 10.1001/jama.2021.24939. JAMA. 2022. PMID: 35029629 Free PMC article. Clinical Trial.
Repeat subcutaneous administration of casirivimab and imdevimab in adults is well-tolerated and prevents the occurrence of COVID-19.
Isa F, Forleo-Neto E, Meyer J, Zheng W, Rasmussen S, Armas D, Oshita M, Brinson C, Folkerth S, Faria L, Heirman I, Sarkar N, Musser BJ, Bansal S, O'Brien MP, Turner KC, Ganguly S, Mahmood A, Dupljak A, Hooper AT, Hamilton JD, Kim Y, Kowal B, Soo Y, Geba GP, Lipsich L, Braunstein N, Yancopoulos GD, Weinreich DM, Herman GA;  for the COVID-19 Multi-dose Trial Team. Isa F, et al. Among authors: hooper at. Int J Infect Dis. 2022 Sep;122:585-592. doi: 10.1016/j.ijid.2022.06.045. Epub 2022 Jul 2. Int J Infect Dis. 2022. PMID: 35788416 Free PMC article. Clinical Trial.
Efficacy and safety of a single dose of casirivimab and imdevimab for the prevention of COVID-19 over an 8-month period: a randomised, double-blind, placebo-controlled trial.
Herman GA, O'Brien MP, Forleo-Neto E, Sarkar N, Isa F, Hou P, Chan KC, Bar KJ, Barnabas RV, Barouch DH, Cohen MS, Hurt CB, Burwen DR, Marovich MA, Musser BJ, Davis JD, Turner KC, Mahmood A, Hooper AT, Hamilton JD, Parrino J, Subramaniam D, Baum A, Kyratsous CA, DiCioccio AT, Stahl N, Braunstein N, Yancopoulos GD, Weinreich DM; COVID-19 Phase 3 Prevention Trial Team. Herman GA, et al. Among authors: hooper at. Lancet Infect Dis. 2022 Oct;22(10):1444-1454. doi: 10.1016/S1473-3099(22)00416-9. Epub 2022 Jul 5. Lancet Infect Dis. 2022. PMID: 35803290 Free PMC article. Clinical Trial.
62 results